Demonstration venue · read-only. Every page can be browsed; the buttons that would change it are switched off. Create an account to run TaxoReview on your own data. A simulation from public publication records: the people listed were not invited and did not agree to review.
? Tutorial for this page

William Laframboise

dblp:425/2694 · DBLP profile ↗
← Back
1ranked-venue papers
0as first author
1since 2021 · last 2025
—ORCID · none

Domains — the database's venue-derived domains; a paper can count in several

Applied, interdisciplinary, general and emerging computing · 1 · 1 since 2021

Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.

Interdisciplinary, comprehensive, and emerging computing
1 paper
Bioinformatics and computational biology · 100%

Topics — the 3 heaviest of 3, each with the papers that count most for it

TopicWeightPapersLastEvidence papers
Bioinformatics and computational biology › cancer genomics
circulating tumor DNA analysis
0.912025
Marker selection strategies for circulating tumor DNA guided by phylogenetic inference · Bioinform. 2025
Bioinformatics and computational biology › cancer genomics › tumor evolution
clonal evolution
0.912025
Marker selection strategies for circulating tumor DNA guided by phylogenetic inference · Bioinform. 2025
Bioinformatics and computational biology › gene expression analysis › gene expression classification
marker gene selection
0.912025
Marker selection strategies for circulating tumor DNA guided by phylogenetic inference · Bioinform. 2025

Methods — techniques the papers use, named apart from their topics

probabilistic modeling · 0.9phylogenetic inference · 0.9optimization · 0.9bootstrap sampling · 0.9
YearPublicationVenuePosition
2025 Marker selection strategies for circulating tumor DNA guided by phylogenetic inference
abstract
MOTIVATION: Blood-based profiling of tumor DNA ("liquid biopsy") offers great prospects for non-invasive early cancer diagnosis and clinical guidance, but requires further computational advances to become a robust quantitative assay of tumor clonal evolution. We propose new methods to better characterize tumor clonal dynamics from circulating tumor DNA (ctDNA), through application to two specific tasks: (i) applying longitudinal ctDNA data to refine phylogeny models of clonal evolution, and (ii) quantifying changes in clonal frequencies that may be indicative of treatment response or tumor progression. We pose these through a probabilistic framework for optimally identifying markers and using them to characterize clonal evolution. RESULTS: We first estimate a density over clonal tree models using bootstrap samples over pre-treatment tissue-based sequence data. We then refine these models over successive longitudinal samples. We use the resulting framework for modeling and refining tree densities to pose a set of optimization problems for selecting ctDNA markers to maximize measures of utility for reducing uncertainty in phylogeny models and quantifying clonal frequencies given the models. We tested our methods on synthetic data and showed them to be effective at refining tree densities and inferring clonal frequencies. Application to real tumor data further demonstrated the methods' effectiveness in refining a lineage model and assessing its clonal frequencies. The work shows the power of computational methods to improve marker selection, clonal lineage reconstruction, and clonal dynamics profiling for more precise and quantitative assays of somatic evolution and tumor progression. AVAILABILITY AND IMPLEMENTATION: https://github.com/CMUSchwartzLab/Mase-phi.git. (DOI: 10.5281/zenodo.14776163).
Xuecong Fu, Zhicheng Luo, Yueqian Deng, William Laframboise, David Bartlett, Russell Schwartz
Bioinform.4